Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2016

View Archived Issues

OncoImmune, Pfizer enter agreement for anti-CTLA-4 monoclonal antibody

Inhibition of midkine as promising new therapeutic strategy to enhance osteoporotic fracture healing

DR6-mediated necroptotic signaling pathways as targets for antimetastatic therapies

RSV F Vaccine does not meet efficacy endpoints in phase III trial in older adults

Johnson & Johnson to acquire Abbott Medical Optics

EMA's CHMP recommends approval of Glyxambi for adults with type 2 diabetes

Retrotope's phase I/II study of RT-001 meets all primary goals

EMA committee recommends E.U. approval of Stelara for moderate to severely active Crohn's disease

Novel mutations found that may cause Wolcott-Rallison syndrome

Topivert initiates phase IIa trial of TOP-1288 in ulcerative colitis

EMA committee recommends approval of Parsabiv in E.U.

New company GammaDelta Therapeutics raises seed funding

Kyowa Kirin initiates first-in-human trial of KHK-2455

NBAS mutations may cause new syndrome associated with type 1 diabetes

EMA committee grants positive opinion for conditional approval of Ninlaro

Dosing begins in Zymeworks' phase I study of ZW-25

Asterias Biotherapeutics reports positive results of AST-OPC1 spinal cord injury trials

TeneoBio obtains license to Ligand Pharmaceuticals' OmniFlic technology

Confirmatory phase III study of PF-06438179 meets primary endpoint

Dr. Reddy's Laboratories and Amgen expand collaboration

Lion Biotechnologies enters two agreements regarding TIL products

GX-H9 shows potential for the treatment of AGHD

Pfizer receives positive CHMP opinion for Ibrance in Europe

MRC-Industry Asset Sharing Initiative makes deprioritized compounds available to researchers

Weekly somapacitan appears more convenient than daily human growth hormone in phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...